Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02194894

The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients

Non-alcoholic Fatty Liver Disease (NAFLD) Clinical Trial

Official title:
The Effect of Daily Acetaminophen on Patients With Non-alcoholic Fatty Liver Disease (NAFLD) Compared to Healthy Controls

Clinical Trial Summary

In this first pilot study, we will examine the effects of acetaminophen dosing in adult patients with NAFLD in comparison to the effects in a healthy control group. Both groups will receive 3 grams (g) of acetaminophen, the maximum recommended daily dose, daily for 14 days. We hypothesize that NAFLD patients are more prone to APAP toxicity than normal controls.Treatment will be stopped after two weeks or in the following conditions:

Treatment with APAP will be stopped in healthy volunteers if ALT and/or AST reached three times the ULN. In patients with NAFLD, treatment will be stopped if: ALT or AST reach ≥ three times the upper limit of entry value or ≥ 5 times the ULN; or if there is ALT or AST >3 times ULN and TBili >2xULN or INR >1.5; or if there is ALT or AST >3 times ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%). We follow a conservative approach derived from the FDA guidelines for stopping medications expected to cause drug induced liver injury (DILI). Indeed, the FDA allows continuation of the medication until ALT or AST are >8x ULN in the absence of elevated Tbili or INR. Patients who have hepatotoxicity will have close monitoring of their liver enzymes until they normalize. Taking acetaminophen up to 3g daily has been shown to be safe and acceptable. We have followed very strict criteria for monitoring and stopping rules however in the usually cases of toxicity the patient will be admitted for monitoring.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02194894
Study type Interventional
Source University of Southern California
Contact
Status Withdrawn
Phase N/A
Start date June 2014
Completion date March 19, 2015
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04099147 - Diagnosis and Characterization of Non-Alcoholic Fatty Liver Disease Based on Artificial Intelligence.
Completed NCT04019561 - A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH. Phase 2
Withdrawn NCT00375349 - Non Alcoholic Fatty Liver Disease Influence of Statin Therapy N/A
Active, not recruiting NCT04682600 - The Sonic Incytes Liver Incytes System, Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF N/A
Terminated NCT02605616 - Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD) Phase 2
Completed NCT04165343 - Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER
Recruiting NCT03151473 - Longitudinal Observational Study Of Chinese With NAFLD/NASH
Recruiting NCT04820036 - A Physiologic Analysis of Endoscopic Sleeve Gastroplasty (ESG) N/A
Active, not recruiting NCT02037321 - Meta-Analyses of the Effect of Vegetable Protein for Animal Protein on Cardiometabolic Risk N/A
Completed NCT01997424 - Association of Non-alcoholic Fatty Liver Disease and Diabetes Mellitus N/A
Completed NCT01110577 - Study of Magnetic Resonance Imaging (MRI) to Quantify Liver Fat in Diabetic and Pre-Diabetic Patients (0000-171) N/A
Completed NCT00771108 - Exercise Dose and Nonalcoholic Fatty Liver Disease N/A
Recruiting NCT04639414 - Combined Active Treatment in Type 2 Diabetes With NASH Phase 4
Completed NCT04450875 - Efficacy of Nutritional Therapy With High Methionine Content in the Treatment of NAFLD N/A
Recruiting NCT02654665 - Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults Phase 3
Recruiting NCT05699018 - Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients N/A
Withdrawn NCT02457286 - Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study Phase 1
Completed NCT01811472 - Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients Phase 2
Completed NCT00968747 - Regulation of FGF21 by Nutritional Challenges N/A
Recruiting NCT04330326 - Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease Phase 2